Compare Heron Therapeutics Inc (HRTX) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs TotalEnergies SE — how do they compare? Heron Therapeutics Inc trades at $0.33 (market cap $63.41M), while TotalEnergies SE trades at $88.39 (market cap $193.69B). The key difference: TotalEnergies SE is far larger — about 3054.6× Heron Therapeutics Inc's market cap, and TotalEnergies SE pays a 4.82% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | TTE | |
|---|---|---|
Market Cap | $63.41M | $193.69B |
Sector | Health | Energy |
52-Week High | $1.49 | $93.60 |
52-Week Low | $0.33 | $57.39 |
Enterprise Value | $161.31M | $224.68B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
TotalEnergies (TTE) trades at $85.83, down 0.51% on the day, with a neutral technical signal. The stock shows attractive valuation metrics, including a P/E of 10.74 and P/S of 0.96, while recent earnings beat expectations in Q1 and Q2 2026. The company is actively reshaping its portfolio, acquiring Shell's European renewables business and developing the Cronos gas field in Cyprus. Cash flow improved in 2025, with net cash flow turning positive to $358 million after two years of outflows.
The outlook is supported by a strong analyst consensus, with a $94 price target and 57.6% buy ratings, but risks include declining revenue trends, legal challenges from climate litigation, and exposure to volatile energy markets. The stock offers a compelling value proposition with solid profitability and strategic investments in both traditional and renewable energy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
